Evaluation of a Hybrid Seed Contract Between Smallholders and an MNC in East Java, Indonesia

Three hundred smallholders near Malang in East Java were surveyed of whom 150 were participating in a hybrid seed contract with Pioneer Hybrid International Inc, an American MNC that has been contracting in the area since 1986. The objectives of the study were to determine whether the contract improved the welfare of those who participated and, if participation did improve welfare, to evaluate why this contract, in contrast to many other farm contracts in developing countries, is successful. A transaction cost framework was used to specify a framework for probit analysis of contract participation and regression analysis used to measure the contribution made by contract participation to gross margins. The empirical results suggest (i) contract selection was by Pioneer and not through self-selection, (ii) the contract is likely to favour larger farmers and (iii) the Pioneer contract improved returns to farm capital and hence was likely to be welfare improving for contractors. The success of the contract over many years was attributed to the nature of the contracting process which was between Pioneer and grower groups and not at the individual smallholder level.Farm Management,

Augmented Reality als Entscheidungshilfe beim Möbelkauf

Diese Studie untersucht den Einfluss von Augmented Reality (AR) auf den Kaufentscheidungsprozess beim Möbelkauf. Ziel der Studie waren konkrete, handlungsleitende und wissenschaftlich fundierte Erkenntnisse für die Praxis im Umgang mit der digitalen Transformation. Dafür wurde der Einfluss einer AR-App in der Möbelbranche untersucht. Es konnte gezeigt werden, dass die AR-App ihren Nutzern eine wertvolle Unterstützung im Kaufentscheidungsprozess bietet. Die App funktioniert jedoch nicht als eigenständiger Kanal, sondern entfaltet ihren Nutzen nur im Zusammenspiel mit den bisherigen Kanälen und Hilfsmitteln. Insbesondere der Austausch mit Dritten bietet deutliches Entwicklungspotenzial und Chancen, die Customer Experience weiter zu verbessern. Einen klaren Kundenmehrwert würde eine händlerübergreifende AR-App bieten. Weiterer Forschungsbedarf ergibt sich aus den Rückkoppelungseffekten zwischen veränderter Kundeninteraktion und Technologieentwicklung

TESS Discovery of an ultra-short-period planet around the nearby M dwarf LHS 3844

Data from the newly-commissioned \textit{Transiting Exoplanet Survey Satellite} (TESS) has revealed a "hot Earth" around LHS 3844, an M dwarf located 15 pc away. The planet has a radius of $1.32\pm 0.02$ $R_\oplus$ and orbits the star every 11 hours. Although the existence of an atmosphere around such a strongly irradiated planet is questionable, the star is bright enough ($I=11.9$, $K=9.1$) for this possibility to be investigated with transit and occultation spectroscopy. The star's brightness and the planet's short period will also facilitate the measurement of the planet's mass through Doppler spectroscopy.Comment: 10 pages, 4 figures. Submitted to ApJ Letters. This letter makes use of the TESS Alert data, which is currently in a beta test phase, using data from the pipelines at the TESS Science Office and at the TESS Science Processing Operations Cente

TESS Discovery of an Ultra-short-period Planet around the Nearby M Dwarf LHS 3844

Data from the newly commissioned Transiting Exoplanet Survey Satellite has revealed a 'hot Earth' around LHS 3844, an M dwarf located 15 pc away. The planet has a radius of R ⊕ and orbits the star every 11 hr. Although the existence of an atmosphere around such a strongly irradiated planet is questionable, the star is bright enough (I = 11.9, K = 9.1) for this possibility to be investigated with transit and occultation spectroscopy. The star's brightness and the planet's short period will also facilitate the measurement of the planet's mass through Doppler spectroscopy

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570